Submission should be made at the
journal of Pharmacy Technology's manuscript submission page.
Upload the manuscript and cover letter in a format compatible with Microsoft
Word for Windows. Combine title page, abstract, text, references, and
table(s) into a single document prior to online submission. Art (eg, figures,
photographs) must be computer-generated or scanned in high resolution
(see also "Figures"). Each figure should be submitted as a separate electronic
file. The Author
Signature Form and other applicable documents (see "Other
Considerations for Manuscript Submission") must be mailed to the Editorial
Office within 10 days of manuscript submission. If online submission is
not possible, a diskette or CD containing the cover letter, manuscript,
and any figures must be mailed to the Editorial Office. Other applicable
documents, as described above, must also be included.
Cover letter. All cover letters
must include the following:
- Name of corresponding author with full mailing address, telephone
and fax numbers, and email address;
- Brief explanation of the topic's significance to practice or patient
- Explanation about any similar work by the author(s) or data from the
same study that is under review or in press, or results previously presented
or published (see "Duplicate Publication");
- Request for anonymity during peer review, if desired (see also "Title
Author Signature Form
Signature form, containing Assignment of Copyright, Criteria for Authorship,
Acknowledgment, and Conflict of Interest must be signed by each author
and received by the journal within 10 days of manuscript submission.
Original signatures of all authors are required; faxed, photocopied, or
scanned signatures are not acceptable.
Assignment of Copyright
Authors must transfer all rights, title, and interest to their manuscript
to Harvey Whitney Books Company, publisher of the journal of Pharmacy
Criteria for Authorship
Authorship criteria are identical to those spelled out in the Uniform
Requirements for Manuscripts Submitted to Biomedical Journals. Specifically,
authorship credit should be based on 1) substantial contributions to conception
and design, acquisition of data, or analysis and interpretation of data;
2) drafting the article or revising it critically for important intellectual
content; and 3) final approval of the version to be published. Authors
should meet conditions 1, 2, and 3. Assistance solely in nonsubstantive
aspects of the submission, for example, the acquisition of funding, assembly
of data, and referral of patients, does not justify authorship. At least
one author must be responsible for each section of the manuscript.
Persons who have contributed significantly to the substance of the paper,
but whose contributions do not justify authorship, should be acknowledged.
Acknowledgment of technical writers must include their sources of funding.
Authors must ensure that all persons named in the acknowledgment, excluding
those providing financial or technical support, have agreed in writing
to be named.
CONSIDERATIONS FOR MANUSCRIPT SUBMISSION
Permission to use copyrighted material: Written permission
(original stamp/signature) from the publisher, organization, or person
who holds copyright is necessary for use of previously published tables,
figures, or other copyrighted material.
Informed consent: Identifying information should not
be present in written descriptions or photographs of persons unless considered
essential for scientific purposes. In such cases, written informed consent
from the person must be obtained by the authors, with documentation included
with manuscript submission.
Duplicate publication: Work
that has been published or is described in an article submitted for publication
elsewhere may not warrant further consideration. It is the corresponding
author's responsibility to inform the editor about all submissions and
previous reports describing the same work.
Rapid publication: If requested, justification of need
should be provided.
Conflict of interest statement:
Authors must report any conflicts of interest, including consulting fees,
paid expert testimony, employment, grants, honoraria, patents, royalties,
stocks, or any other relationships or ethical considerations that may
involve the subject matter of the manuscript and compromise its integrity.
If there are no conflicts, authors should make a statement of this fact.
Research Reports: Original research
involving medication effectiveness, safety, or pharmacy practice. Meta-analyses
are also considered research. Well-designed prospective studies are given
highest priority for acceptance. Limitations of studies must be stated
in the text. All reports must include, when applicable, a statement in
the Methods section that the work was conducted in compliance with Institutional
Review Board/Human Subjects Research Committee requirements.
Review Articles: Comprehensive,
significant, critical, and analytical reviews that include essential information
on a well-delineated subject. Some articles are selected for the journal's
continuing education program (PharmaCE),
for which the author provides a goal, objectives, and questions according
to guidelines available from the Editorial Office. Reviews must synthesize
and critically evaluate available data rather than simply describing the
findings. Articles are classified using the subcategories below:
Case Reports: New or unusual events
in one or more patients that expand the knowledge about common disease
states or provide significant information about drug safety, adverse reactions,
or interactions. Clinical and laboratory data and concurrent medications
or diseases should be documented. Case reports describing adverse events
should adhere to the International Society for Pharmacoepidemiology and
International Society of Pharmacovigilance's Guidelines for submitting
adverse event reports for publication (Pharmacoepidemiol Drug Saf 2007;16:581-7.
Before submitting a report of an adverse drug reaction, the Naranjo ADR
probability scale (Clin Pharmacol Ther 1981;30:239-45) or other validated
and appropriate scale should be used to assess the likelihood that the
events were drug-related. Likewise, for reports of drug interactions,
the DIPS scale (Ann Pharmacother 2007;41:674-80. DOI
10.1345/aph.1H423) or another validated scale should be applied. Ranking
from the scale must be included in both abstract and text. Priority is
given to cases for which the scores indicate a probable or definite association.
Commentaries: Viewpoints on diverse,
controversial, or topical subjects. Contact
the Editorial Office prior to submission.
Letters and Comments: Letters
and comments should address areas related to clinical practice, research,
or education, including recently published articles. Letters are limited
to no more than five authors. In cases where adverse effects or drug interactions
are described, the Naranjo ADR probability scale or DIPS scale, respectively,
should be used to determine the likelihood that the adverse effect was
drug-related (see "Case Reports"). Comments must be submitted within 6
months of an article's publication.
Authors are required to follow the journal's style, which is
consistent with the Uniform
Requirements for Manuscripts Submitted to Biomedical Journals.
Other useful style references are the American Medical Association
Manual of Style; Scientific Style and Format: The CSE Manual for Authors,
Editors and Publishers; and The Chicago Manual of Style.
Manuscript Preparation: Manuscripts
should be prepared using a 12-point font on 8.5 x 11.0 inch (216 x 279
mm) paper (ISO A4 also acceptable), with margins of at least 1 inch (25
mm). All copy should be double-spaced, including title page, abstract,
text, acknowledgments, references, tables, and figure legends. Pages must
Title Page: The title page
- Article title (concise, but indicating main focus of paper);
- Name of each author as it should appear in print;
- Highest academic degree, position title, and/or academic appointment
of each author;
- Names of departments and institutions with which each author is affiliated;
- Name, address, telephone and fax numbers, and email address of corresponding
- Name, address, fax number, and email address of author to whom reprint
requests should be sent, if different from corresponding author;
- Statement pertaining to funding and conflict of interest (see "Conflict
of Interest Statement");
- Information about presentation of the work as an abstract or poster,
- Separate word counts of abstract and main text; and
- Key words for purposes of indexing and searching.
Authors desiring anonymity during peer review
must request this in the cover letter and provide a second copy of the
manuscript with all identifying information removed and a title page with
only items 1, 7, 8, 9, and 10.
Structured Abstract: Abstracts
should be no more than 300 words. See abstracts in any recent issue of
the journal for examples of proper abstract subheadings and content. Reference
citations are not used in the abstract.
Text: Appropriate headings and subheadings
should be used liberally throughout the text. Abbreviations must be defined
upon first use in the text. Use of abbreviations should be limited to,
for example, lengthy terms; the majority of drug names should not be abbreviated.
USANs or, when appropriate, chemical names, must be used for all drugs.
Manufacturers' code numbers should be used only when a generic name is
not yet available. Trade names should be included only to distinguish
between different trade preparations, for some combination drugs, or in
reviews of drugs that have been recently approved by the FDA.
References: All references,
including those related primarily to figures and tables, must appear in
the text and be cited consecutively. References in text, tables, and figure
legends should be denoted with superscript Arabic numerals. Personal communications
(ie, unpublished data) may not be used as numbered references. Information
obtained through personal communication must be inserted in parentheses
within the text and include the contact person's name, academic degree,
affiliation, and date of communication. Signed permission letters from
quoted sources indicating the content of the personal communication must
be provided to the Editorial Office. Abstracts and Letters to the Editor
may be used as numbered references but must be identified as such in the
citations. Inclusive pagination must be provided for all references. Journal
names should be abbreviated as they appear in PubMed. Those not appearing
in PubMed should be spelled out. Referenced articles that are cited as
"In press" must include the title of the journal that has accepted the
paper. List all authors when there are 6 or fewer; with 7 or more authors,
list the first 3, followed by et al. To facilitate online retrieval of
references, include a citation's digital object identifier (DOI) if available.
More information about DOIs can be obtained at www.crossref.org
or dx.doi.org. When citing
articles that have been published online prior to print, authors are encouraged
to include the date published online (Epub date) in addition to the full
print information. When the article has appeared in print, the URL will
not be used; however, a DOI should be included if available. Examples
of correct referencing style are given below.
Baldwin DS, Heldbo Reines E, Guiton C, Weiller E. Escitalopram therapy
for major depression and anxiety disorders. Ann Pharmacother 2007;41:1583-92.
Epub 11 Sept 2007. DOI 10.1345/aph.1K089
- ARTICLE WITH URL
Centers for Disease Control and Prevention. Strongyloidiasis. www.dpd.cdc.gov/dpdx/HTML/Strongyloidiasis.htm
(accessed 2007 Aug 17).
Rao N, Knebel W, Bergsma T, et al. Population pharmacokinetics of istradefylline
(abstract 13). J Clin Pharmacol 2007;47:1185.
- JOURNAL SUPPLEMENT
Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation executive
summary: Joint American College of Chest Physicians/American Association
of Cardiovascular and Pulmonary Rehabilitation Evidence-Based Clinical
Practice Guidelines. Chest 2007;131(suppl):1S-3S. DOI 10.1378/chest.07-0892
- JOURNAL OR MAGAZINE PAGINATED BY ISSUE
Vyzral K. Legislative update. Ohio Pharmacist 2007;56(9):17.
- BOOK CHAPTER
Shah M, Cunningham MJ. Toxicogenomics. In: Gad SC, ed. Handbook of pharmaceutical
biotechnology. 1st ed. Hoboken, NJ: John Wiley & Sons, Inc., 2007:229-51.
- PACKAGE INSERT
Product information. Zantac (ranitidine). Research Triangle Park, NC:
GlaxoSmithKline, June 2007.
- SCIENTIFIC PRESENTATION
Davis TM, Yeap B, Bruce DG, Davis WA. Lipid-lowering therapy protects
against peripheral sensory neuropathy in type 2 diabetes. Presented
at: 67th Scientific Sessions. American Diabetes Association Annual Meeting,
Chicago, IL, June 22, 2007.
- MONOGRAPH IN ELECTRONIC FORMAT
Tamoxifen. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex,
expires 2007 Dec 31 (accessed 2007 Jan 11).
Appendices: When necessary, appendices
should be used to present lengthy or detailed surveys, descriptions of
extensive mathematical calculations, and/or itemized lists. They should
be placed (with legends as needed) following the reference list in the
manuscript. Lengthy appendices, such as algorithms, surveys, and protocols,
will be published only online; the URL will be provided in the printed
article where the appendix is cited.
Tables: Each table must be double-spaced
on a separate page. A brief title must be provided for each table. Each
column requires a brief descriptive heading. Explanations and full terms
for abbreviations used should appear alphabetically below the body of
table. Statistical measures of variation (ie, standard deviation) should
be identified in footnotes (designated as a, b, c, etc.). The units of
measure used for all data in a column should be indicated. Internal horizontal
or vertical rules should not be used. Duplication of table content within
text should be minimized.
Figures: Figures should be computer
generated, photographed, or professionally drawn and submitted as a PDF
(photographs 300 dpi; line art 1200 dpi). Original hard copies or electronic
files are required; photocopies are not acceptable. Each figure should
be provided as a separate page or electronic file. Figures generated in
PowerPoint, as well as freehand or with typewritten lettering, are unacceptable.
Send an electronic version of each figure or 2 sharp, glossy originals
of photographs; sharp laser copies of line art are acceptable. Letters,
numbers, and symbols should be clear, uniform in size, and large and dark
enough to be legible when the size of the figure is reduced to fit column
width in the journal. Titles and detailed explanations should appear in
the legends rather than in the figures. Bar graphs or pie charts should
be in black and white only and not contain gray shading as filler or background;
distinctive fillings should be used instead (eg, white or solid black;
horizontal, vertical, or slanted stripes; cross-hatching; dots). Dotted
lines and decimal points should be dark enough to reproduce well. Background
horizontal or vertical lines should not be used. Figures should have labels
on their margins or backs indicating file number, figure number, and corresponding
author’s name at top of figure. The top of a figure should also be designated
on the back if the figure lacks distinguishing features. Legends should
be double-spaced, and each abbreviation and symbol used must be defined.
Duplication of figure content within text should be minimized.